Read this company snapshot
Daily valuation snapshot
Unicycive Therapeutics, Inc. Common Stock: source evidence dated 2026-10-09.
- Daily close (USD)
- $4.11
- Market capitalization (USD)
- $114,485,106.27
- Price / earnings (TTM)
- Not reported
- Price / book
- 2.15
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research UNCY in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research UNCY in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb RZB 012 for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also evaluates licensing of technologies and drugs for orphan diseases, other renal, liver, and other metabolic diseases affecting fibrosis and inflammation. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd to develop and commercialize oxylanthanum carbonate; Sphaera Pharma Pte. Ltd.; Syneos Health LLC to develop of UNI-494; Inotiv for preclinical trial and related services for oxylanthanum carbonate and UNI-494; Lee's Pharmaceutical (HK) Limited; and Lotus International Pte Ltd for the development, registration filing, and approval for oxylanthanum carbonate. The company was incorporated in 2016 and is based in Los Altos, California.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing UNCY with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $4.11 |
| Market capitalization (USD) | $114,485,106.27 |
| Price / earnings (TTM) | Not reported |
| Price / book | 2.15 |
No matching rows. Clear the filter to see all records.
Read UNCY's valuation metrics
Company size
Unicycive Therapeutics, Inc. Common Stock's recorded market capitalization is $114,485,106.27. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
UNCY's recorded price-to-book ratio is 2.15. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Unicycive Therapeutics, Inc. Common Stock with Aurora
Use the snapshot above to ask a specific question about UNCY. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow UNCY's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.